ARCHIVES

Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says

This article is from The Cancer Letter archive.

Vol. 20 No. 33 | August 19, 1994

Download PDF Visit The Full Archive

Related Articles

In Brief: Panel to Meet June 9 In Boston; Iverson Takes Position At U. Colo.’Namovicz Leaving NHLBI

May 23, 1986

NCI CTEP Approved Trials For the Month of February

February 22, 2013

In Brief: Blumberg, Comis, Skalka Named Fox Chase VPs; Howard Temin Appointed To NCAB

June 5, 1987

NIH Faces Cuts Under House, Senate, Administration Plans

May 19, 1995

NCAB Says President’s Budget Would “Seriously Damage” Cancer Program

February 12, 1999

Anticancer Vaccine Trials Due In Three-Four Years; Virus Research Opportunities Described

July 25, 1975